Moors & Cabot Inc. Purchases Shares of 5,200 Vera Therapeutics, Inc. (NASDAQ:VERA)

Moors & Cabot Inc. purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERAFree Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 5,200 shares of the company’s stock, valued at approximately $220,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. AlphaQuest LLC bought a new position in shares of Vera Therapeutics in the 4th quarter worth approximately $34,000. KBC Group NV raised its position in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares in the last quarter. E Fund Management Co. Ltd. raised its position in shares of Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after acquiring an additional 1,130 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Vera Therapeutics by 109.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company’s stock worth $416,000 after acquiring an additional 4,914 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Vera Therapeutics in the 3rd quarter worth approximately $475,000. Institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on VERA. Wells Fargo & Company began coverage on Vera Therapeutics in a research report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 target price for the company. The Goldman Sachs Group started coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price for the company. Guggenheim upped their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. Finally, Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $64.67.

Read Our Latest Stock Report on Vera Therapeutics

Vera Therapeutics Stock Performance

Shares of VERA opened at $27.99 on Monday. The business’s fifty day simple moving average is $33.01 and its two-hundred day simple moving average is $39.64. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 12 month low of $25.99 and a 12 month high of $51.61. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -10.72 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERAGet Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.11. Research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. This trade represents a 16.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 21.70% of the company’s stock.

Vera Therapeutics Company Profile

(Free Report)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Featured Articles

Institutional Ownership by Quarter for Vera Therapeutics (NASDAQ:VERA)

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.